[ JAK2 mutation in myeloproliferative neoplasms: a predictive factor of thrombosis]
Tunisie Medicale [La]. 2015; 93 (7): 474-477
em Francês
| IMEMR
| ID: emr-177380
ABSTRACT
Background:
BCR-ABL negative myeloproliferative neoplasms [MPN] include polycythemia Vera [PV], essential thrombocythemia [ET] and primitive myelofibrosis [PMF]. the JAK2 V617F mutation has been introduced since 2008 as a major diagnostic criterion on the one hand and on the other hand, it would be linked to increased risk of thrombotic complications
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Francês
Revista:
Tunisie Med.
Ano de publicação:
2015
Similares
MEDLINE
...
LILACS
LIS